As the recent high-profile pulling from the market of a pegylated peptide (Omontys by Affymax) due to hypersensitivity, even anaphylactic reactions demonstrate (and also the infusion reactions reported by Alnylam in their SNALP RNAi Therapeutics trials), administration-related hypersensitivity reactions are an issue for the entire drug development arena. In order to rescue the value of a number of blockbuster franchises, I expect that changing administration schedules could be one area attracting increased attention. A patent here could have unexpected value.
The efforts above are a reminder that cancer could be an even bigger commercial opportunity for RNAi Therapeutics than liver-related indications. The genome-wide targeting opportunity with RNAi Therapeutics has not been lost. The pharmaceutical industry is watching.
Register for the GTC RNAi Research and Therapeutics meeting in San Francisco today (June 20-21). Get a free RNAi Therapeutics blog T-shirt and 20% discount on registration by entering discount code 'RNABLG13'.